GLP1R and Hyperglycemia: Moreover, novel GLP-1R/GIPR dual agonists have been introduced for the clinical treatment of hyperglycaemia and T2DM, which show synergistic and superior metabolic effects compared to single incretin receptor agonists (Finan et al., 2013; Frias et al., 2017, 2018).